Product Description
Allopurinol is used to treat gout, high levels of uric acid in the body caused by certain cancer medications, and kidney stones. Allopurinol is in a class of medications called xanthine oxidase inhibitors. It works by reducing the production of uric acid in the body. High levels of uric acid may cause gout attacks or kidney stones. Allopurinol is used to prevent gout attacks, not to treat them once they occur. (Sourced from: https://medlineplus.gov/druginfo/meds/a682673.html)
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Leukemia | Lymphoma | Oncology Solid Tumor Unspecified | Oncology Unspecified | Gout
Known Adverse Events: Kidney Diseases | Gastroesophageal Reflux | Influenza, Human
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, Estonia, Finland, Germany, Italy, Netherlands, Norway, Poland, Portugal, Spain, Switzerland, United States, Unknown Location
Active Clinical Trial Count: 15
Highest Development Phases
Phase 3: Brain Death|Brain Injuries|Congenital Heart Defects|Gout|Hypothermia|Hypoxia-Ischemia, Brain
Phase 2: Autism Spectrum Disorder|Epilepsy|Heart Failure, Chronic|Heart Failure, Diastolic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CRUCIAL | P3 |
Recruiting |
Congenital Heart Defects |
2026-10-31 |
|
| ALBINO | P3 |
Recruiting |
Hypoxia-Ischemia, Brain|Brain Injuries |
2026-01-31 |
|
| D0120-205 | P2 |
Recruiting |
Gout |
2025-07-31 |
|
| EURELIA2 | P3 |
Recruiting |
Gout |
2025-07-01 |
34% |
| EURELIA2 | P3 |
Recruiting |
Gout |
2025-07-01 |
34% |